Fig. 2

The effect of MSC-CM on OCC proliferation and the inhibitory effects of GB. MSC-CM promoted the proliferation of non-mucinous OCCs such as SKOV3, DOV13, OVCA433, ES2 and TOV112D cells but had no effect on mucinous OCCs such as RMUG-L, 3AO, and OMC685 cells. No significant differences were observed between 24 h and 48 h. a The non-mucinous OCC line SKOV3 showed dose-dependent responses to PAF treatment, a strong response to MSC-CM and significant increases in cell proliferation. The proliferation-inducing effect of MSC-CM was almost the same as that induced by stimulation with PAF at a high concentration (100 ng/ml). Compared with treatment with PAF alone and vehicle control, treatment with the PAFR antagonist ginkgolide B (GB) (100 μmol/l) significantly blocked PAF-induced and MSC-CM-induced cell proliferation. b The proliferation of the mucinous OCC line OMC685 (with negative PAFR expression) was not affected by PAF treatment and MSC-CM. “*” indicates a statistically significant difference between different groups